Skip to main content

Advertisement

Table 2 Quality of assessment for included trials

From: Effectiveness and safety of prolotherapy injections for management of lower limb tendinopathy and fasciopathy: a systematic review

Study Pathology A B C D E F G H I Total/18 Quality assessment Allocation concealment
Kim et al. [35] PF 1 1 0 0 2 2 2 2 2 12 Moderate B
Lyftogt [30] AT 0 0 0 0 0 0 1 2 2 5 Poor C
Lyftogt [31] AT 0 0 0 0 0 0 1 1 2 4 Poor C
Maxwell et al. [32] AT 0 1 0 0 0 2 2 2 2 9 Moderate C
Ryan et al. [36] PF 0 2 0 0 0 2 2 1 2 9 Moderate C
Ryan et al. [33] AT 0 1 0 0 0 2 1 1 2 7 Moderate C
Topol et al. [37] OSD 1 2 1 1 1 2 2 2 2 14 Good B
Yelland et al. [34] AT 2 2 2 0 0 2 2 2 2 14 Good A
  1. PF Plantar fasciopathy, AT Achilles tendinopathy, OSD Osgood-Schlatter disease, A concealed assignment, B withdrawals described, intention to treat analysis, C assessors blinded, D participant blinded, E groups comparable at entry, F identical care programs, G inclusions/exclusions defined, H interventions defined, I outcomes defined